Ankit Kansagra, Medical Oncologist at Tampa General Hospital, shared on LinkedIn:
“The week’s most important result: an individualized mRNA neoantigen therapy added to pembrolizumab raised 24-month recurrence-free survival in resected melanoma from 70.0% to 82.2% in a 1,137-patient phase 3 trial (NEJM).
Week in Oncology, Nov 7-13. Five items, and what I took from each.
- Individualized mRNA neoantigen therapy plus pembrolizumab lowers melanoma recurrence (Phase 3)
The curves separate only after six months. From running a cell therapy program, I want to see manufacturing turnaround before assuming this travels beyond trial sites. - Durvalumab plus enfortumab vedotin before cystectomy approved for cisplatin-ineligible bladder cancer (FDA approval)
EFS hazard ratio 0.51 against surgery alone. The trial leaves open how three pre-op cycles of EV compare with the perioperative EV regimen already on label. - A bispecific antibody-drug conjugate improves survival in second-line esophageal squamous cancer (Phase 3)
OS 9.79 vs 7.20 months, with grade 3 or higher treatment-related toxicity in 85%, all in China. The regulatory path elsewhere is the open question. - Gut microbiome diversity did not predict non-relapse mortality after allogeneic transplant (Phase 3 companion study)
As a transplant physician, I read this as a caution: the GVHD regimen that won clinically looked worse on the microbiome. - Pimicotinib approved for tenosynovial giant cell tumor (FDA approval)
Response rate 56% vs 3.2% on placebo. The harder decision is how long to continue a daily kinase inhibitor in a tumor that is rarely life-threatening.
Health systems will soon be asked to deliver per-patient manufactured products in the adjuvant setting.
Which of these five would be hardest for your program to put into practice?”
Other articles from Ankit Kansagra on OncoDaily.